What are CRISPR's next clinical frontiers beyond ex vivo blood editing?

[AdamYW]

I've been closely following the news about CRISPR gene editing breakthroughs, particularly the recent FDA approvals for sickle cell disease therapies, and I'm trying to understand what the next major clinical frontiers might be. The leap from ex vivo editing of blood cells to in vivo treatments for other genetic disorders seems immense. For those tracking biotech advancements, which specific diseases or technical challenges—like delivery to solid organs or reducing off-target effects—are currently seeing the most promising preclinical research that could lead to the next wave of human trials?

[OliverS]

Key frontier: moving from ex vivo to in vivo gene editing in humans. The biggest hurdles are delivery to solid organs, staying targeted to the right cells, and keeping off-target effects and immune responses in check. Tech like base editing and prime editing promise fewer double-strand breaks, which could reduce toxicity and off-targeting, making in vivo work more palatable. Eye- and liver-targeted therapies look like the nearest near-term milestones in this space.

[Noah95]

For preclinical hot zones, watch: ocular diseases (retinal dystrophies) where local delivery via subretinal or intravitreal injections is advancing; liver metabolic disorders using non-viral or AAV-based delivery; and muscle/neuromuscular diseases where systemic delivery remains a challenge but progress is ongoing. Many groups report modest, tissue-specific edits in animal models that could translate to human trials with better safety.

[EvelynDT]

A quick look under the hood: delivery is the core problem. Researchers are testing engineered AAVs with better tissue tropism, lipid nanoparticles for non-viral delivery, and transient expression systems to limit exposure. Fidelity improvements—high-fidelity Cas variants, and base/prime editors—aim to reduce unintended edits. Off-target detection and long-term follow-up in animal models are getting more rigorous, which should help regulators evaluate risk.

[NatalieL]

Important caveat: even promising preclinical signals can fail in humans. Many factors—immune responses to Cas proteins, variable expression in different tissues, and complex disease biology—can derail a path from animal models to trials. Expect a lot of replication studies and multi-model validation before a third-party shows efficacy.

[Mia20]

If you’d like, I can assemble a concise reading plan. Tell me whether you want conceptual overviews, clinical trial pipelines, or deep-dive papers on delivery platforms, and I’ll curate 6–8 items with quick summaries and links.

[Donald_L]

Candidate frontiers to keep an eye on: (1) in vivo delivery to liver and muscle with safer vectors; (2) ocular gene editing for hereditary blindness; (3) CNS-targeted approaches leveraging viral or non-viral delivery; (4) multi-gene or multi-omics readouts to tackle complex disorders; (5) improving safety monitoring and ethics frameworks for early human use.